Bumol Thomas F.
Known title: DirectorCIK: 0001767077
Associated companies
Transaction History
| OMER | ▲ Buy | Grant | 10,000 | $33K | 9/12/2023 | View on chart |
| OMER | ▲ Buy | Grant | 10,000 | $33K | 9/12/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cantor Fitzgerald upgrades Omeros to Overweight with $22 target
Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 price target, citing potential for its transplant drug. The stock recently hit a five-year peak, reflecting growing investor interest. This move aligns with broader analyst optimism, as the average target price stands at $27.50.
Cantor Fitzgerald upgrades Omeros to Overweight with $22 target. Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 price target, citing potential for its transplant drug. The stock recently hit a five-year peak, reflecting growing investor interest. This move aligns with broader analyst optimism, as the average target price stands at $27.50.